{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:06:26Z","timestamp":1790251586389,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL130020"],"award-info":[{"award-number":["R01 HL130020"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI183953"],"award-info":[{"award-number":["U01 AI183953"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AI195484"],"award-info":[{"award-number":["U01 AI195484"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UG3 AG097135"],"award-info":[{"award-number":["UG3 AG097135"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UG3 TR005845"],"award-info":[{"award-number":["UG3 TR005845"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 TR006031"],"award-info":[{"award-number":["UM1 TR006031"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["23CDA1050577"],"award-info":[{"award-number":["23CDA1050577"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["24POST1198670"],"award-info":[{"award-number":["24POST1198670"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005188","name":"Tobacco-Related Disease Research Program","doi-asserted-by":"publisher","award":["T34KT7965"],"award-info":[{"award-number":["T34KT7965"]}],"id":[{"id":"10.13039\/100005188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Protoc"],"DOI":"10.1038\/s41596-026-01445-8","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:28:29Z","timestamp":1790249309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["New approach methodologies: drug screening platform to identify antifibrotic compounds"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2646-0959","authenticated-orcid":false,"given":"Hao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9731-8562","authenticated-orcid":false,"given":"Lu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5399-0074","authenticated-orcid":false,"given":"Rihua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renke","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9886-5058","authenticated-orcid":false,"given":"David E.","family":"Solow-Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Souhrid","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-8041","authenticated-orcid":false,"given":"Joseph C.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"1445_CR1","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41392-022-01070-3","volume":"7","author":"M Zhao","year":"2022","unstructured":"Zhao, M. et al. Targeting fibrosis: mechanisms and clinical trials. Signal Transduct. Target. Ther. 7, 206 https:\/\/doi.org\/10.1038\/s41392-022-01070-3 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1445_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41573-025-01158-9","volume":"24","author":"F Rieder","year":"2025","unstructured":"Rieder, F. et al. Fibrosis: cross-organ biology and pathways to development of innovative drugs. Nat. Rev. Drug Discov. 24, 543\u2013569 https:\/\/doi.org\/10.1038\/s41573-025-01158-9 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1445_CR3","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1016\/j.cell.2021.06.024","volume":"184","author":"MV Plikus","year":"2021","unstructured":"Plikus, M. V. et al. Fibroblasts: origins, definitions, and functions in health and disease. Cell 184, 3852\u20133872 https:\/\/doi.org\/10.1016\/j.cell.2021.06.024 (2021).","journal-title":"Cell"},{"key":"1445_CR4","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","volume":"587","author":"NC Henderson","year":"2020","unstructured":"Henderson, N. C., Rieder, F. & Wynn, T. A. Fibrosis: from mechanisms to medicines. Nature 587, 555\u2013566 https:\/\/doi.org\/10.1038\/s41586-020-2938-9 (2020).","journal-title":"Nature"},{"key":"1445_CR5","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1093\/cvr\/cvaa324","volume":"117","author":"NG Frangogiannis","year":"2021","unstructured":"Frangogiannis, N. G. Cardiac fibrosis. Cardiovasc. Res. 117, 1450\u20131488 https:\/\/doi.org\/10.1093\/cvr\/cvaa324 (2021).","journal-title":"Cardiovasc. Res."},{"key":"1445_CR6","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrcardio.2017.57","volume":"14","author":"MD Tallquist","year":"2017","unstructured":"Tallquist, M. D. & Molkentin, J. D. Redefining the identity of cardiac fibroblasts. Nat. Rev. Cardiol. 14, 484\u2013491 https:\/\/doi.org\/10.1038\/nrcardio.2017.57 (2017).","journal-title":"Nat. Rev. Cardiol."},{"key":"1445_CR7","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.addr.2021.03.021","volume":"173","author":"M Liu","year":"2021","unstructured":"Liu, M., L\u00f3pez de Juan Abad, B. & Cheng, K. Cardiac fibrosis: myofibroblast-mediated pathological regulation and drug delivery strategies. Adv. Drug Deliv. Rev. 173, 504\u2013519 https:\/\/doi.org\/10.1016\/j.addr.2021.03.021 (2021).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"1445_CR8","doi-asserted-by":"publisher","first-page":"e148554","DOI":"10.1172\/jci148554","volume":"132","author":"JG Travers","year":"2022","unstructured":"Travers, J. G., Tharp, C. A., Rubino, M. & McKinsey, T. A. Therapeutic targets for cardiac fibrosis: from old school to next-gen. J. Clin. Invest. 132, e148554 https:\/\/doi.org\/10.1172\/jci148554 (2022).","journal-title":"J. Clin. Invest."},{"key":"1445_CR9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrd.2017.111","volume":"16","author":"JG Moffat","year":"2017","unstructured":"Moffat, J. G., Vincent, F., Lee, J. A., Eder, J. & Prunotto, M. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Nat. Rev. Drug Discov. 16, 531\u2013543 https:\/\/doi.org\/10.1038\/nrd.2017.111 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1445_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110643","volume":"39","author":"CY Huang","year":"2022","unstructured":"Huang, C. Y. et al. Population-based high-throughput toxicity screen of human iPSC-derived cardiomyocytes and neurons. Cell Rep. 39, 110643 https:\/\/doi.org\/10.1016\/j.celrep.2022.110643 (2022).","journal-title":"Cell Rep."},{"key":"1445_CR11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1161\/atvbaha.120.314695","volume":"41","author":"CK Lam","year":"2021","unstructured":"Lam, C. K. & Wu, J. C. Clinical trial in a dish: using patient-derived induced pluripotent stem cells to identify risks of drug-induced cardiotoxicity. Arterioscler. Thromb. Vasc. Biol. 41, 1019\u20131031 https:\/\/doi.org\/10.1161\/atvbaha.120.314695 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"1445_CR12","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1124\/pr.116.013003","volume":"72","author":"DT Paik","year":"2020","unstructured":"Paik, D. T., Chandy, M. & Wu, J. C. Patient and disease-specific induced pluripotent stem cells for discovery of personalized cardiovascular drugs and therapeutics. Pharmacol. Rev. 72, 320\u2013342 https:\/\/doi.org\/10.1124\/pr.116.013003 (2020).","journal-title":"Pharmacol. Rev."},{"key":"1445_CR13","doi-asserted-by":"publisher","first-page":"7143","DOI":"10.1016\/j.cell.2024.09.034","volume":"187","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target. Cell 187, 7143\u20137163.e22 https:\/\/doi.org\/10.1016\/j.cell.2024.09.034 (2024).","journal-title":"Cell"},{"key":"1445_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1146\/annurev-pharmtox-022724-095035","volume":"65","author":"Z Yildirim","year":"2025","unstructured":"Yildirim, Z., Swanson, K., Wu, X., Zou, J. & Wu, J. Next-gen therapeutics: pioneering drug discovery with iPSCs, genomics, AI, and clinical trials in a dish. Annu. Rev. Pharmacol. Toxicol. 65, 71\u201390 https:\/\/doi.org\/10.1146\/annurev-pharmtox-022724-095035 (2025).","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"1445_CR15","doi-asserted-by":"publisher","first-page":"0003","DOI":"10.1038\/s41551-016-0003","volume":"1","author":"X Bao","year":"2017","unstructured":"Bao, X. et al. Long-term self-renewing human epicardial cells generated from pluripotent stem cells under defined xeno-free conditions. Nat. Biomed. Eng. 1, 0003 https:\/\/doi.org\/10.1038\/s41551-016-0003 (2017).","journal-title":"Nat. Biomed. Eng."},{"key":"1445_CR16","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1161\/circresaha.119.315491","volume":"125","author":"H Zhang","year":"2019","unstructured":"Zhang, H. et al. Generation of quiescent cardiac fibroblasts from human induced pluripotent stem cells for in vitro modeling of cardiac fibrosis. Circ. Res. 125, 552\u2013566 https:\/\/doi.org\/10.1161\/circresaha.119.315491 (2019).","journal-title":"Circ. Res."},{"key":"1445_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1161\/circresaha.120.316958","volume":"127","author":"AA Gibb","year":"2020","unstructured":"Gibb, A. A., Lazaropoulos, M. P. & Elrod, J. W. Myofibroblasts and fibrosis: mitochondrial and metabolic control of cellular differentiation. Circ. Res. 127, 427\u2013447 https:\/\/doi.org\/10.1161\/circresaha.120.316958 (2020).","journal-title":"Circ. Res."},{"key":"1445_CR18","doi-asserted-by":"publisher","first-page":"11473","DOI":"10.1073\/pnas.0604348103","volume":"103","author":"J Inglese","year":"2006","unstructured":"Inglese, J. et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl Acad. Sci. USA 103, 11473\u201311478 https:\/\/doi.org\/10.1073\/pnas.0604348103 (2006).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1445_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100216","volume":"2","author":"P Mamoshina","year":"2021","unstructured":"Mamoshina, P., Rodriguez, B. & Bueno-Orovio, A. Toward a broader view of mechanisms of drug cardiotoxicity. Cell Rep. Med. 2, 100216 https:\/\/doi.org\/10.1016\/j.xcrm.2021.100216 (2021).","journal-title":"Cell Rep. Med."},{"key":"1445_CR20","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nm.4087","volume":"22","author":"PW Burridge","year":"2016","unstructured":"Burridge, P. W. et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat. Med. 22, 547\u2013556 https:\/\/doi.org\/10.1038\/nm.4087 (2016).","journal-title":"Nat. Med."},{"key":"1445_CR21","doi-asserted-by":"publisher","first-page":"eaaf2584","DOI":"10.1126\/scitranslmed.aaf2584","volume":"9","author":"A Sharma","year":"2017","unstructured":"Sharma, A. et al. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. Sci. Transl. Med. 9, eaaf2584 https:\/\/doi.org\/10.1126\/scitranslmed.aaf2584 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1445_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39099-9","volume":"14","author":"AB Alber","year":"2023","unstructured":"Alber, A. B. et al. Directed differentiation of mouse pluripotent stem cells into functional lung-specific mesenchyme. Nat. Commun. 14, 3488 https:\/\/doi.org\/10.1038\/s41467-023-39099-9 (2023).","journal-title":"Nat. Commun."},{"key":"1445_CR23","doi-asserted-by":"publisher","first-page":"100314","DOI":"10.1016\/j.crmeth.2022.100314","volume":"2","author":"K Tamai","year":"2022","unstructured":"Tamai, K. et al. iPSC-derived mesenchymal cells that support alveolar organoid development. Cell Rep. Methods 2, 100314 https:\/\/doi.org\/10.1016\/j.crmeth.2022.100314 (2022).","journal-title":"Cell Rep. Methods"},{"key":"1445_CR24","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s42003-024-06419-8","volume":"7","author":"T Kobayashi","year":"2024","unstructured":"Kobayashi, T., Yamashita, A., Tsumaki, N. & Watanabe, H. Subpopulations of fibroblasts derived from human iPS cells. Commun. Biol. 7, 736 https:\/\/doi.org\/10.1038\/s42003-024-06419-8 (2024).","journal-title":"Commun. Biol."},{"key":"1445_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13287-018-0958-2","volume":"9","author":"Y Kim","year":"2018","unstructured":"Kim, Y. et al. Establishment of a complex skin structure via layered co-culture of keratinocytes and fibroblasts derived from induced pluripotent stem cells. Stem Cell Res. Ther. 9, 217 https:\/\/doi.org\/10.1186\/s13287-018-0958-2 (2018).","journal-title":"Stem Cell Res. Ther."},{"key":"1445_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.stem.2018.05.027","volume":"23","author":"M Coll","year":"2018","unstructured":"Coll, M. et al. Generation of hepatic stellate cells from human pluripotent stem cells enables in vitro modeling of liver fibrosis. Cell Stem Cell 23, 101\u2013113.e7 https:\/\/doi.org\/10.1016\/j.stem.2018.05.027 (2018).","journal-title":"Cell Stem Cell"},{"key":"1445_CR27","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1016\/j.stemcr.2021.11.002","volume":"16","author":"Y Koui","year":"2021","unstructured":"Koui, Y. et al. Development of human iPSC-derived quiescent hepatic stellate cell-like cells for drug discovery and in vitro disease modeling. Stem Cell Rep. 16, 3050\u20133063 https:\/\/doi.org\/10.1016\/j.stemcr.2021.11.002 (2021).","journal-title":"Stem Cell Rep."},{"key":"1445_CR28","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1161\/circresaha.120.317791","volume":"128","author":"RM Burke","year":"2021","unstructured":"Burke, R. M. et al. Prevention of fibrosis and pathological cardiac remodeling by salinomycin. Circ. Res. 128, 1663\u20131678 https:\/\/doi.org\/10.1161\/circresaha.120.317791 (2021).","journal-title":"Circ. Res."},{"key":"1445_CR29","doi-asserted-by":"publisher","first-page":"e123987","DOI":"10.1172\/jci.insight.123987","volume":"4","author":"M Rehman","year":"2019","unstructured":"Rehman, M. et al. High-throughput screening discovers antifibrotic properties of haloperidol by hindering myofibroblast activation. JCI Insight 4, e123987 https:\/\/doi.org\/10.1172\/jci.insight.123987 (2019).","journal-title":"JCI Insight"},{"key":"1445_CR30","doi-asserted-by":"publisher","first-page":"4679","DOI":"10.1073\/pnas.1702750114","volume":"114","author":"MJ Bollong","year":"2017","unstructured":"Bollong, M. J. et al. Small molecule-mediated inhibition of myofibroblast transdifferentiation for the treatment of fibrosis. Proc. Natl Acad. Sci. USA 114, 4679\u20134684 https:\/\/doi.org\/10.1073\/pnas.1702750114 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1445_CR31","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.jacbts.2019.10.008","volume":"4","author":"GA Van Norman","year":"2019","unstructured":"Van Norman, G. A. Limitations of animal studies for predicting toxicity in clinical trials: is it time to rethink our current approach? JACC Basic Transl. Sci. 4, 845\u2013854 https:\/\/doi.org\/10.1016\/j.jacbts.2019.10.008 (2019).","journal-title":"JACC Basic Transl. Sci."},{"key":"1445_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1161\/circresaha.122.321475","volume":"132","author":"M Rubino","year":"2023","unstructured":"Rubino, M. et al. Inhibition of eicosanoid degradation mitigates fibrosis of the heart. Circ. Res. 132, 10\u201329 https:\/\/doi.org\/10.1161\/circresaha.122.321475 (2023).","journal-title":"Circ. Res."},{"key":"1445_CR33","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1161\/circulationaha.119.042559","volume":"141","author":"K Schimmel","year":"2020","unstructured":"Schimmel, K. et al. Natural compound library screening identifies new molecules for the treatment of cardiac fibrosis and diastolic dysfunction. Circulation 141, 751\u2013767 https:\/\/doi.org\/10.1161\/circulationaha.119.042559 (2020).","journal-title":"Circulation"},{"key":"1445_CR34","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nrd1900","volume":"4","author":"KA O\u2019Connor","year":"2005","unstructured":"O\u2019Connor, K. A. & Roth, B. L. Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat. Rev. Drug Discov. 4, 1005\u20131014 https:\/\/doi.org\/10.1038\/nrd1900 (2005).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1445_CR35","doi-asserted-by":"publisher","first-page":"L276","DOI":"10.1152\/ajplung.00087.2019","volume":"318","author":"M Tisler","year":"2020","unstructured":"Tisler, M. et al. Analysis of fibroblast migration dynamics in idiopathic pulmonary fibrosis using image-based scaffolds of the lung extracellular matrix. Am. J. Physiol. Lung Cell. Mol. Physiol. 318, L276\u2013L286 https:\/\/doi.org\/10.1152\/ajplung.00087.2019 (2020).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"1445_CR36","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1091\/mbc.e03-05-0352","volume":"15","author":"W Li","year":"2004","unstructured":"Li, W. et al. Mechanism of human dermal fibroblast migration driven by type I collagen and platelet-derived growth factor-BB. Mol. Biol. Cell 15, 294\u2013309 https:\/\/doi.org\/10.1091\/mbc.e03-05-0352 (2004).","journal-title":"Mol. Biol. Cell"},{"key":"1445_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3389\/fphar.2014.00123","volume":"5","author":"RT Kendall","year":"2014","unstructured":"Kendall, R. T. & Feghali-Bostwick, C. A. Fibroblasts in fibrosis: novel roles and mediators. Front. Pharmacol. 5, 123 https:\/\/doi.org\/10.3389\/fphar.2014.00123 (2014).","journal-title":"Front. Pharmacol."},{"key":"1445_CR38","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1161\/circresaha.124.323892","volume":"134","author":"N Cadosch","year":"2024","unstructured":"Cadosch, N., Gil-Cruz, C., Perez-Shibayama, C. & Ludewig, B. Cardiac fibroblastic niches in homeostasis and inflammation. Circ. Res. 134, 1703\u20131717 https:\/\/doi.org\/10.1161\/circresaha.124.323892 (2024).","journal-title":"Circ. Res."},{"key":"1445_CR39","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1053\/j.gastro.2019.05.002","volume":"157","author":"AA Widjaja","year":"2019","unstructured":"Widjaja, A. A. et al. Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in mouse models of nonalcoholic steatohepatitis. Gastroenterology 157, 777\u2013792.e14 https:\/\/doi.org\/10.1053\/j.gastro.2019.05.002 (2019).","journal-title":"Gastroenterology"},{"key":"1445_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11703","volume":"7","author":"S Bhattacharyya","year":"2016","unstructured":"Bhattacharyya, S. et al. Tenascin-C drives persistence of organ fibrosis. Nat. Commun. 7, 11703 https:\/\/doi.org\/10.1038\/ncomms11703 (2016).","journal-title":"Nat. Commun."},{"key":"1445_CR41","doi-asserted-by":"publisher","unstructured":"Zhang, H. et al. 3-Dimensional human iPSC-derived cardiac organoids for antifibrotic drug screening. Circ. Res. https:\/\/doi.org\/10.1161\/circresaha.126.328797 (2026).","DOI":"10.1161\/circresaha.126.328797"},{"key":"1445_CR42","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature24676","volume":"552","author":"S Schafer","year":"2017","unstructured":"Schafer, S. et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature 552, 110\u2013115 https:\/\/doi.org\/10.1038\/nature24676 (2017).","journal-title":"Nature"},{"key":"1445_CR43","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1476-5381.2009.00207.x","volume":"159","author":"CE Pollard","year":"2010","unstructured":"Pollard, C. E. et al. An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk. Br. J. Pharmacol. 159, 12\u201321 https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00207.x (2010).","journal-title":"Br. J. Pharmacol."},{"key":"1445_CR44","doi-asserted-by":"publisher","first-page":"22.4.1","DOI":"10.1002\/cptx.2","volume":"68","author":"M Clements","year":"2016","unstructured":"Clements, M. Multielectrode array (MEA) assay for profiling electrophysiological drug effects in human stem cell-derived cardiomyocytes. Curr. Protoc. Toxicol. 68, 22.4.1\u201322.4.32 https:\/\/doi.org\/10.1002\/cptx.2 (2016).","journal-title":"Curr. Protoc. Toxicol."},{"key":"1445_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yjmcc.2015.12.031","volume":"91","author":"T Moore-Morris","year":"2016","unstructured":"Moore-Morris, T., Cattaneo, P., Puceat, M. & Evans, S. M. Origins of cardiac fibroblasts. J. Mol. Cell. Cardiol. 91, 1\u20135 https:\/\/doi.org\/10.1016\/j.yjmcc.2015.12.031 (2016).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"1445_CR46","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41586-025-08945-9","volume":"642","author":"S Cho","year":"2025","unstructured":"Cho, S. et al. Selective inhibition of stromal mechanosensing suppresses cardiac fibrosis. Nature 642, 766\u2013775 https:\/\/doi.org\/10.1038\/s41586-025-08945-9 (2025).","journal-title":"Nature"},{"key":"1445_CR47","doi-asserted-by":"publisher","first-page":"102492","DOI":"10.1016\/j.scr.2021.102492","volume":"55","author":"H Zhang","year":"2021","unstructured":"Zhang, H. et al. Generation of three induced pluripotent stem cell lines (SCVIi014-A, SCVIi015-A, and SCVIi016-A) from patients with LQT1 caused by heterozygous mutations in the KCNQ1 gene. Stem Cell Res 55, 102492 https:\/\/doi.org\/10.1016\/j.scr.2021.102492 (2021).","journal-title":"Stem Cell Res"},{"key":"1445_CR48","doi-asserted-by":"publisher","unstructured":"Sharma, A. et al. Derivation of highly purified cardiomyocytes from human induced pluripotent stem cells using small molecule-modulated differentiation and subsequent glucose starvation. J. Vis. Exp. e52628 https:\/\/doi.org\/10.3791\/52628 (2015).","DOI":"10.3791\/52628"},{"key":"1445_CR49","doi-asserted-by":"publisher","first-page":"15112","DOI":"10.1038\/s41598-019-51676-x","volume":"9","author":"T Grune","year":"2019","unstructured":"Grune, T., Ott, C., H\u00e4seli, S., H\u00f6hn, A. & Jung, T. The \u201cMYOCYTER\u201d\u2014convert cellular and cardiac contractions into numbers with ImageJ. Sci. Rep. 9, 15112 https:\/\/doi.org\/10.1038\/s41598-019-51676-x (2019).","journal-title":"Sci. Rep."},{"key":"1445_CR50","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1161\/circresaha.117.312067","volume":"122","author":"L Sala","year":"2018","unstructured":"Sala, L. et al. MUSCLEMOTION: a versatile open software tool to quantify cardiomyocyte and cardiac muscle contraction in vitro and in vivo. Circ. Res. 122, e5\u2013e16 https:\/\/doi.org\/10.1161\/circresaha.117.312067 (2018).","journal-title":"Circ. Res."},{"key":"1445_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2022.101144","volume":"3","author":"S Scalzo","year":"2022","unstructured":"Scalzo, S., Mendon\u00e7a, C., Kushmerick, C., Agero, U. & Guatimosim, S. Microscopy-based cellular contractility assay for adult, neonatal, and hiPSC cardiomyocytes. STAR Protoc. 3, 101144 https:\/\/doi.org\/10.1016\/j.xpro.2022.101144 (2022).","journal-title":"STAR Protoc."},{"key":"1445_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-49653-5","volume":"9","author":"N Kumar","year":"2019","unstructured":"Kumar, N. et al. Assessment of temporal functional changes and miRNA profiling of human iPSC-derived cardiomyocytes. Sci. Rep. 9, 13188 https:\/\/doi.org\/10.1038\/s41598-019-49653-5 (2019).","journal-title":"Sci. Rep."},{"key":"1445_CR53","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1161\/circresaha.118.314202","volume":"125","author":"CK Lam","year":"2019","unstructured":"Lam, C. K. et al. Identifying the transcriptome signatures of calcium channel blockers in human induced pluripotent stem cell-derived cardiomyocytes. Circ. Res. 125, 212\u2013222 https:\/\/doi.org\/10.1161\/circresaha.118.314202 (2019).","journal-title":"Circ. Res."},{"key":"1445_CR54","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3389\/fphys.2020.00612","volume":"11","author":"PT Wright","year":"2020","unstructured":"Wright, P. T., Tsui, S. F., Francis, A. J., MacLeod, K. T. & Marston, S. B. Approaches to high-throughput analysis of cardiomyocyte contractility. Front. Physiol. 11, 612 https:\/\/doi.org\/10.3389\/fphys.2020.00612 (2020).","journal-title":"Front. Physiol."}],"container-title":["Nature Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41596-026-01445-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41596-026-01445-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41596-026-01445-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:28:31Z","timestamp":1790249311000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41596-026-01445-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":54,"alternative-id":["1445"],"URL":"https:\/\/doi.org\/10.1038\/s41596-026-01445-8","relation":{},"ISSN":["1754-2189","1750-2799"],"issn-type":[{"value":"1754-2189","type":"print"},{"value":"1750-2799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.C.W. is a co-founder and advisory board member of Greenstone Biosciences. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}